Duke University grants license to develop medical treatment for neurological disorders
Bloom Science is granted the exclusive option by Duke University to license microbiome-based intellectual property and technology for the development of transformational medical treatment that targets neurological disorders, as well as oncology-related disorders.
Duke University has announced the signing of an agreement with biopharmaceutical company, Bloom Science. This agreement grants intellectual property rights to the company for all isolates and strains of the Akkermansia genus bacteria, as well as the technology related to strain isolates was developed in the laboratory of lead researcher, Raphael H. Valdivia, Ph.D.
The driving force behind this agreement is Bloom’s aim to discover and develop precision living medicines for neurological disorders that are not currently treatable. Bloom Science has extensive plans to leverage on the technology developed by Valdivia as well as his team to develop therapeutics for neurological disorders.
The underlying principle of Valdivia’s research is to isolate, characterise and genetically alter the Akkermansia strain of bacteria. This extensive research has led the team to understand how this beneficial microbe’s genes contribute to the treatment of disorders as well as the restoration of immunological health.
Consequently, Valvidia who will be joining Bloom as a scientific founder adds “We are very excited for the opportunity to generate Akkermansia strains with the most beneficial activities and accelerate their application as potential therapeutics.”
Bloom Science will leverage the technology used by the team to develop the heirloom strain of Akkermansia therapeutics. This is the genetically optimised strain of the bacteria and will be used to discover the novel chemical composition of the Akkermansia metabolome.
According to CEO of Bloom Science, Christopher Reyes, PhD, “Valdivia and his team’s extensive research will be essential to our therapeutic development platform and furthers our strategy of investing in and expanding our multi-faceted approach to leveraging the gut-brain axis to discover and develop breakthrough therapies for the largest number of patients.”
Extensive research corroborates this statement: The concept of “gut-brain axis” includes complicated direct and indirect interaction of miroorganisms found in the human gut and the central nervous system.
These microorganisms produce metabolites with different cellular components that interact with central nervous system.
Changes or disruptions to these microoganisms in the human gut will also lead to changes in the central nervous system. This then results in the progression of various central nervous system and neurological disorders.
Reyes cites the success of animal testing that shows the potential of this strain of bacteria in treating various medical conditions including amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, immune oncology, progeroid syndrome and other metabolic diseases.
Akkermansia is a genus of bacteria that has been found by studies to improve metabolic health. Extensive studies have demonstrated the correlation between healthy gut bacteria and improvements in neurological conditions.
In fact, researchers have found that the particular strain of Akkermansia muciniphila were more abundant in mice fed a ketogenic diet, and that these bacteria were sufficient to protect mice fed a normal diet against seizures.
Reyes adds that the success of numerous animal studies demonstrate the high therapeutic potential of Akkermansia muciniphila.